ORYZON announces new Global Chief Business Officer and expansion of US corporate activities

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announce...

Read more

ORYZON to present new clinical data and corporate updates at international conferences in September and October

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today...

Read more

ORYZON receives approval to start EVOLUTION Phase IIb trial with vafidemstat in schizophrenia

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today...

Read more

ORYZON enrolls first patient in PORTICO, a Phase IIb clinical trial with vafidemstat in Borderline Personality Disorder

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today...

Read more

ORYZON announces FDA Orphan Drug Designation granted to iadademstat for treatment of Acute Myeloid Leukemia

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today an...

Read more

ORYZON to present a corporate update and to hold multiple virtual corporate activities in January-2021

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announce...

Read more

Sartorius to open new Customer Interaction Center in North America

by Sartorius Stedim Spain

Sartorius, a leading international partner of life science research and the biopharmaceutical industry, is expanding its presence in Massachusetts with a North American Customer Interaction Center. Sa...

Read more

Oryzon announces appointment of Dr. Torsten Hoffmann as Global R&D Director and retirement of Dr. Tamara Maes

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announce...

Read more

AI for biopharmaceutical production – Sartorius a new shareholder in DFKI, the German Research Center for Artificial Intelligence

by Sartorius Stedim Spain

Sartorius has joined the group of shareholders of the German Research Center for Artificial Intelligence (DFKI). The Göttingen-based life science group and DFKI have already been working together for...

Read more

Sartorius successfully places note loan with a volume of 750 million euros

by Sartorius Stedim Spain

Sartorius, a leading international partner of life science research and the biopharmaceutical industry, successfully placed a note loan with a volume of 750 million euros.

Read more

ORYZON to present at upcoming international conferences

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today...

Read more

Resolutions of the Annual Shareholders’ Meeting of Sartorius AG

by Sartorius Stedim Spain

At today’s virtual Annual General Shareholders’ Meeting, shareholders granted discharge to the Executive Board and the Supervisory Board and approved the boards’ proposals by a large majority. T...

Read more
Subscribe to Directory
Write an Article

Recent News

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Novel T-cell bispecific antibody shows p...

by VHIO

First results of two multi-center international Phase 1 dose-escalatio...

Photos Stream